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The EMBO Journal REFEREE REPORTS
Referee #1
Jiang et al. describe in this manuscript a negative regulation of the Wnt/β-Catenin signaling by the adaptor protein Disabled-2 (Dab2) through the direction of the Wnt co-receptor LRP6 into the clathrin-positive endocytic compartment. The direct Dab2-LRP6 interaction is regulated by a caseinkinase 2 (CK2)-phosphorylation of LRP6 on S1579. The present work supports the suggested "two pathways-two outcome model" for canonical Wnt signaling in which caveolin-mediated endocytosis triggers the signal, while the clathrin-mediated incorporation disables it by degradation of the LRP6 co-receptor. Furthermore, this work also supports the multivesicular endosome model for Wnt signaling. This convincing work is well presented and seems to me of high importance for the Wnt field. I recommend the publication of this work in EMBO journal, however, I have few suggestions in order to further improve the manuscript:
Major comments:
-In the presented model, Dab2 binds directly to phosphor-S1579 on LRP6 in order to trigger clathrin-mediated endocytosis and degradation for LRP6. This Serine on position S1579 is a target for casein-kinase 2 (CK2) and is not phosphorylated when the cells were exposed to Wnt. How do the authors explain the regulation of phosphorylation on this site? Why is CK2 not able to phosphorylate this site on LRP6 upon Wnt signaling? This should be discussed explicitly in the text.
-The results presented in Figure 3E were obtained using Apigenin, a CK2 inhibitor. To further support these results, it may be helpful to repeat these experiments in a gene reporter assay, like BAR-Luciferase of SuperTopFlash. This would give a direct readout of the Wnt signaling when the CK2 phosphorylation of LRP6 is inhibited.
-The cellular localization studies presented in supplementary Figure S1 are very informative and should be a part of the main figures. A suitable place would be at the beginning of the manuscript as a stand-alone Figure 1 or 2 or as a part of Figure 1 . To make space Figure 6 could be moved to the supplementary information.
-The authors state that Axin and GSK3 are not localized in the LRP6 receptor-complex when Dab2 is present. This should also be shown in cellular localization studies.
Minor comments:
-In Figure 7C the authors present the model in which clathrin-mediated endocytosis does not inhibit β-Catenin degradation. I think that the inhibitory arrow on the right side is slightly misleading. There should no arrow be placed between the β-Catenin-destruction complex and the vesicle, because the complex is not affected by the clathrin endosome (there is no recruitment of Axin/GSK3 or CK1 to the vesicle). In addition, on the left side GSK3 should be shown binding to LRP6 and Axin, for this explains the sequestration in multivesicular endosomes.
-In the experiment presented in Figure 3D it is not obvious which construct was used. In the main text it is stated that the deltaNG construct was used, but in the figure itself the schematics of the fulllength gene is used.
-Page 14, first paragraph: please correct the sentence "In the presence of Dab2, LRP6 is internalized..." to: "In the presence of Dab2 and CK2 phosphorylation of LRP6, the co-receptor is internalized..." -Page 14, last paragraph: The sentence: "In Dab2/clathrin-containing endosomes, ..." is too long, please break it up to make it more understandable.
Referee #2
In the submitted manuscript, Howe and colleagues studies the role of Dab2 in the control of canonical and non-canonical Wnt signaling. They show that Dab2, which inhibits canonical Wnt signaling, does so by binding to and sequestering LRP6 to a clathrin-dependent endocytic route. The authors identify the residue S1579 in LRP as the responsible residue. They further demonstrate the importance of this residue and Dab2 in xenograft and co-injection assays in zebrafish.
The control of signaling specificity between canonical and non-canonical Wnt pathways is a longstanding and still quite unresolved question. Previous studies (in particular by the Kikuchi lab) has demonstrated that the endocytic route that Wnt receptors are directed to determine their effect on different downstream pathways. Dab2 has been also previously implicated in Wnt signaling but its exact molecular role has not been defined.
The main contribution of the manuscript is that the authors link Dab2 to trafficking of LRP6 into the clathrin-coated vesicles with the docking of Dab2 to S1579. Most experiments are well controlled and conclusive. My main criticism of the study is that the advance in my view ois probably not sufficient to warrant publication in a journal targeting a general audience. Both Dab2 and the sorting into different endocytic routes have been previously reported and the current extension of these findings -while interesting to the LRP6 community -might be more suitable for a specialized journal.
Other points:
1. How do the authors align the findings in this study with their previous results on Dab2/Axin interactions (Jiang et al., Oncogene 2009)? Are there multiple protein interactions of Dab2 influencing the Wnt pathway? How do these findings relate with respect to molecular mechanism and physiological relevance? 2. Fig 3D: from the data shown here I am not convinced that S1579 is the only site that influences LRP6-DAP2 binding. This seems to me a bit selective interpretation of the results. 
Referee #3
This study describes the inhibitory mechanism of Dab2 for Wnt/β-catenin signaling. The authors showed that Wnt stimulates CK2-dependent phosphorylation of LRP6, thereby inducing the binding of LRP6 and Dab2 and its internalization via a clathrin route. They also found that S1579 of LRP6 is a phosphorylation site by CK2 and demonstrated the importance of this site in experiments with dorsoventral patterning of zebrafish and allograft mouse tumor models. Overall, the experiments are well designed and the results are fairly convincing. However, there are several points to be addressed to strengthen the authors' data.
(1) The authors showed results obtained from one stable cell line that expresses Dab2 or its mutant. This reviewer is concerned about clonal variation effects in this kind of experiment. How many stable cell lines did the authors use for each experiment? The data using other clones should be shown.
(2) The authors proposed that the negative regulation of Dab2 for Wnt signaling is due to its promotion of clathrin-mediated internalization of LRP6. However, Fig. 1B and Fig. 1E showed that treatment with MDC does not affect the inhibition of Wnt signaling by Dab2. These results suggest that clathrin-mediated endocytosis is not required for the role of Dab2. The authors should test effects of clathrin knockdown on Dab2's ability to suppress Wnt/β-catenin signaling. If clathrin knockdown did not affect the inhibitory ability of Dab2, more simple interpretation would be that Wnt-dependent binding of LRP6 and Dab2 removes LRP6 from caveolin containing fractions to clathrin-containing fractions independently of internalization, thereby preventing the binding of the Axin complex to phosphorylated LRP6.
(3) Dkk1 has been proposed that it competes with Wnt for the binding to LRP6 but does not affect the internalization of LRP6 (Semenov, et al. J. Biol. Chem. 283, 21427-21432, 2008) . In addition, it has also been shown that Dkk1 induces the internalization of LRP6 through a clathrin-mediated route, thereby suppressing Wnt signaling (Yamamoto, et al. Dev. Cell 15:37-48, 2008; Sakane, et al. J. Cell Sci. 123: 360-368, 2010) . Although the inhibitory mechanism by Dkk1 is not yet clear, the authors should discuss the mechanistic difference between Dab2 and Dkk1.
4) It was reported that CK2 phosphorylates dishevelled and act as a positive role in Wnt/β-catenin pathway (Willert, et al. EMBO J. 16: 3089-3096, 1997; Bernatik, et al., J. Biol. Chem. 286: 10396-10410, 2011) . Therefore, the data with siRNA for CK2 must be interpreted carefully in Fig. 7A . The authors should test effects of CK2 knockdown on Wnt-dependent TOP activity in F9 cells and show whether CK2 is required for the Wnt/β-catenin signaling in this cell line. 5) Because the authors' conclusion is based on overexpression of Dab2, to show its physiological relevance for Wnt signaling by loss-of-function experiments would be nice. It should be tested effects of Dab2 knockdown on Wnt-dependent LRP6 phosphorylation, β-catenin accumulation, and Axin2 expression in RA-treated F9 cells in Fig. 3F .
6) The authors should add enlarged pictures in Fig. S1 to show clear colocalization of LRP6 with caveolin or clathrin. In addition, quantitative analysis is required in this experiment. 7) Involvement of a clathrin-mediated route in Wnt5a/PCP signaling was shown in an EMBO J paper (Sato, et al. 29: 41-54, 2010) , which should be cited in this manuscript.
Referee #4
This manuscript presents a beautifully comprehensive analysis of Dab2's role in LRP6 inactivation. The authors use biochemical and in vivo techniques in both zebrafish and mouse to identify a phosphorylation site in the LRP6 carboxy-terminus that is critical to signaling. This work presents an important corroboration of the proposed "two endocytic routes" model for Wnt signal transduction. My main objection to the manuscript as written is that the authors assume that the S1579 phosphorylation is itself the Dab2 docking site -indeed they state this explicitly in their discussion section. However there are no data to support this assumption, and no reason to think that a phosphotyrosine binding domain would possess the capacity to recognize and bind a phosphoserine. It seems much more likely that the S1579 phosphorylation may be a priming event that allows phosphorylation of a Tyr, much as some beta-catenin phosphorylations are priming events for further phosphorylation. I would also have liked to see whether the S1579A mutant LRP6 fails to partition with the clathrin fractions in Wnt-induced F9-Dab2 cells. This would strengthen the authors' contention that Dab2 controls the clathrin versus caveolin sorting of LRP6.
In general, the authors need to be more careful in their wording, and more explicit in some of their descriptions. For example, nowhere in the Results, Methods, or Figure legends is there a statement of which phospho-site on LRP6 is recognized by the anti-p-LRP6 antibody used in Fig. 2C . As this antibody apparently only detects the LRP6 that associates with the caveolin fraction, the reader would have to divine that this refers to a phospho-site other than S1579 or else be hopelessly confused. Likewise, there is no description of what apigenin is or is expected to do within the cell. Why is this included in Fig. 3E ? What is the reader supposed to derive from this observation?
Other minor points: - Fig. 1 -the reader is left to wonder whether nystatin vs. MDC treatment would alter the biotin protection shown in 1F. Why was this not included? - Fig. 2C , the LRP6 distribution does not correlate tightly with the caveolin-enriched fractions. The authors need to comment on why this is the case.
-on pg. 8, the authors claim that they mutagenized "all possible phosphorylation sites" -does this refer only to S/T phosphorylation? or do they know that none of the Tyr's in this region are phosphorylated? -in Fig. 3G , the authors need to comment on the multiple bands revealed in the anti-Dab2 blot. Is the fastest-migrating band a background band or is it an isoform that is resistant to the siDab2 treatment? -in Fig. 5D , the labels are not aligned properly -in Fig. 7C , the schematic diagram does not indicate GSK being sequestered along with Axin in the caveolin pathway, yet this seems to demonstrated in Fig. 2D . Referee 1
1. In the presented model, Dab2 binds directly to phosphor-S1579 on LRP6 in order to trigger clathrin-mediated endocytosis and degradation for LRP6. This Serine on position S1579 is a target for casein-kinase 2 (CK2) and is not phosphorylated when the cells were exposed to Wnt. How do the authors explain the regulation of phosphorylation on this site? Why is CK2 not able to phosphorylate this site on LRP6 upon Wnt signaling? This should be discussed explicitly in the text. Actually, this S1579 site is phosphorylated in response to Wnt stimulation and it is the mutant S1579A that is not (Figure 4 ). In addition, we show that purified CK2 and Wnt-stimulated CK2 can phosphorylate LRP6 at Ser1579 ( Figure S7 ). The mutant S1579A is not phosphorylated by purified CK2. Figure 3E (new Figure 4E) were obtained using Apigenin, a CK2 inhibitor. To further support these results, it may be helpful to repeat these experiments in a gene reporter assay, like BAR-Luciferase of SuperTopFlash. This would give a direct readout of the Wnt signaling when the CK2 phosphorylation of LRP6 is inhibited.
The results in
We performed this experiment requested by the referee using TOP/FOPFlash and the results demonstrate that inhibition of CK2 with apigenin does in fact modulate Dab2's inhibitory activity on Wnt signaling. This new data is presented in Figure S8 . Figure S1 are very informative and should be a part of the main figures. A suitable place would be at the beginning of the manuscript as a stand-alone Figure 1 or 2 or as a part of Figure 1 . To make space Figure 6 could be moved to the supplementary information.
The cellular localization studies of
We have moved the cellular localization studies from the Supplementary figures and now include them as Figure 3 .
The authors state that Axin and GSK3 are not localized in the LRP6 receptor-complex when
Dab2 is present. This should also be shown in cellular localization studies.
As requested by the referee, we have performed additional cellular localization studies demonstrating that Axin and GSK3 are not localized in the LRP6 receptor complex in the presence of Dab2. These new data are presented in Figure S5 . Figure 7C (new Figure 8C) the authors present the model in which clathrin-mediated endocytosis does not inhibit β-catenin degradation. I think that the inhibitory arrow on the right side is slightly misleading. There should no arrow be placed between the β-Catenin-destruction complex and the vesicle, because the complex is not affected by the clathrin endosome (there is no recruitment of Axin/GSK3 or CK1 to the vesicle). In addition, on the left side GSK3 should be shown binding to LRP6 and Axin, for this explains the sequestration in multivesicular endosomes.
In
As requested we changed the arrow to a " ┴ " to indicate no effect or inhibition of interaction, and have altered the Gsk3/Axin/LRP6 diagram. This is now shown as Figure 8C .
6. In Figure 3D (new Figure 4D) it is not obvious which construct was used. In the main text it is stated that the deltaNG construct was used, but in the figure itself the schematics of the fulllength gene is used.
As requested we clarified the sentence to read 'we performed in situ mutagenesis of all possible phosphorylation sites within the rNG construct region of Flag-tagged full length LRP6'.
7. Page 14, first paragraph: please correct the sentence "In the presence of Dab2, LRP6 is internalized..." to: "In the presence of Dab2 and CK2 phosphorylation of LRP6, the co-receptor is internalized...". Page 14, last paragraph: The sentence: "In Dab2/clathrin-containing endosomes, ..." is too long, please break it up to make it more understandable.
We corrected the text according to the referee's suggestions.
Referee 2
How do the authors align the findings in this study with their previous results on Dab2/Axin interactions (Jiang et al., Oncogene 2009)? Are there multiple protein interactions of Dab2
influencing the Wnt pathway? How do these findings relate with respect to molecular mechanism and physiological relevance? According to our model presented in this work, we show that in the presence of Dab2 and Wnt3A stimulation, CK2 mediates phosphorylation of LRP6 on S1579. This site then serves to promote interaction of Dab2 and LRP6, resulting in sequestration of LRP6/Dab2 into clathrincoated pits due to Dab2's ability to interact with clathrin. Following endocytosis in clathrin vesicles, we postulate that the Axin/Dvl/β-catenin complex is recruited to the receptor complex, as it is presumably in the absence of Dab2 in caveolin vesicle; however, now instead of binding to the LRP6 and activating the β-catenin complex, Axin binds Dab2 and is prevented from interaction with and activation of LRP6 (i.e. phosphorylation of LRP6 by the β-catenin complex). In support of this, we have previously demonstrated Axin/Dab2 interactions (Jiang et al., 2009), and we show herein that both Dab2 and Axin bind to the same region of LRP6 (i.e. the 5X-reiterated PPPSP motif of LRP6). Thus, as the reviewer suggests, Dab2 is a classical adaptor, with numerous interactions mediating its inhibitory activity on Wnt signaling. In addition, we demonstrate that this molecular mechanism is of significance during dorsaventral patterning in zebrafish & during tumorigenesis in xenograft mouse models. Figure 4D) : from the data shown here I am not convinced that S1579 is the only site that influences LRP6-DAB2 binding. This seems to me a bit selective interpretation of the results.
Fig 3D (new
We have performed a more comprehensive analysis as suggested by the referee, mutating all of the possible phosphorylation sites within the ΔNG region, and found that only the S1579A mutant abolishes LRP6/Dab2 interactions (see Figure 4D and Figure S6A ). In addition, we also performed a TOP/FOPFlash luciferase activity assay in F9-Dab2 cells with the various phosphomutant LRP6 ΔNG constructs. The results presented in Figure S6B demonstrate that all the phosphomutant LRP6 constructs are attenuated by Dab2 in their ability to transactivate the promoter, except for the S1579A mutant. This indicates that the S1579A phosphomutant can still transactivate the TOP/FOPFlash promoter due to its inability to bind to and be inhibited by Dab2. Figure 5B/ We performed a more comprehensive dorsoventral analysis in zebrafish and quantitated the expression of the various proteins following modulation in zebrafish. The results presented in Figure S11 confirm our previous data and suggest that the resulting phenotypes are not due to varying expression levels. Figure S3 .
Fig 4B/C (new
2. The authors proposed that the negative regulation of Dab2 for Wnt signaling is due to its promotion of clathrin-mediated internalization of LRP6. However, Fig. 1B and Fig. 1E 3. Dkk1 has been proposed that it competes with Wnt for the binding to LRP6 but does not affect the internalization of LRP6 (Semenov, et al. J. Biol. Chem. 283, 21427-21432, 2008) . In addition, it has also been shown that Dkk1 induces the internalization of LRP6 through a clathrin-mediated route, thereby suppressing Wnt signaling (Yamamoto, et al. Dev. Cell 15:37-48, 2008; Sakane, et al. J. Cell Sci. 123: 360-368, 2010) . Although the inhibitory mechanism by Dkk1 is not yet clear, the authors should discuss the mechanistic difference between Dab2 and Dkk1.
As the referee suggested we performed additional experiments to analyze the effects of clathrin and caveolin knockdown on Dab2's inhibitory effects on Wnt signaling. These new data are presented in Figure S1 and demonstrate that caveolin knockdown blocks Wnt/β-catenin signaling in F9 cells, whereas clathrin knockdown attenuates the inhibitory effect of Dab2 on Wnt/β-catenin signaling in F9-Dab2 cells. Thus, monodansylcadaverine (MDC) that inhibits clathrin-mediated endocytosis has no effect on Dab2's inhibitory effect whereas clathrin knockdown does. This indicates, as the referee accurately points out, that the inhibitory effects of Dab2 do not require clathrin-mediated endocytosis but rather interaction with clathrin, suggesting that sequestration of the LRP6 receptor toward clathrin and away from caveolin is required for Dab2's effects. We discuss this point in greater detail in the revised Discussion (p.15) and also highlight key mechanistic differences between the inhibitory effects of DKK1 and Dab2 on Wnt signaling. We have also revised the manuscript to make clear that Dab2's inhibitory effect does not require LRP6 endocytosis.
4. It was reported that CK2 phosphorylates dishevelled and act as a positive role in Wnt/βcatenin pathway (Willert, et al. EMBO J. 16: 3089-3096, 1997; Bernatik, et al., J. Biol. Chem. 286: 10396-10410, 2011) . Therefore, the data with siRNA for CK2 must be interpreted carefully in Fig. 7A (new Figure 8A) . The authors should test effects of CK2 knockdown on Wnt-dependent TOP activity in F9 cells and show whether CK2 is required for the Wnt/bcatenin signaling in this cell line.
We performed the experiment that the referee suggested and demonstrate that CK2 knockdown in F9 cells does not have any significant effect on Wnt/β-catenin signaling. The new data is presented in Figure S12 .
5. It should be tested effects of Dab2 knockdown on Wnt-dependent LRP6 phosphorylation, βcatenin accumulation, and Axin2 expression in RA-treated F9 cells in Fig. 3F (new Figure 4F) .
As the referee suggested we analyzed Wnt-induced phospho-LRP6, Axin 2 and β-catenin accumulation in RA-treated F9 and Dab2 knockdown F9 cells. The results presented in Figure  S10 demonstrate that in RA-treated F9 cells Wnt3A-mediated signaling is attenuated whereas in RA-treated siDab2 F9 cells it is not. Fig. S1 to show clear colocalization of LRP6 with caveolin or clathrin. In addition, quantitative analysis is required in this experiment. We did as the referee suggested. The new data is presented in Figure 3 and Figure S4 .
The authors should add enlarged pictures in
7. Involvement of a clathrin-mediated route in Wnt5a/PCP signaling was shown in an EMBO J paper (Sato, et al. 29: 41-54, 2010) , which should be cited in this manuscript. We referred to this great work and cited it in the revised Introduction.
Referee 4 1. My main objection to the manuscript as written is that the authors assume that the S1579 phosphorylation is itself the Dab2 docking site -indeed they state this explicitly in their discussion section. However there are no data to support this assumption, and no reason to think that a phosphotyrosine binding domain would possess the capacity to recognize and bind a phosphoserine. It seems much more likely that the S1579 phosphorylation may be a priming event that allows phosphorylation of a Tyr, much as some beta-catenin phosphorylations are priming events for further phosphorylation.
In the revised manuscript we have performed a more comprehensive phosphomutagenesis analysis of the ΔNG region of the LRP6 receptor and demonstrate that when all the possible phosphorylation sites are mutated only the S1579 phosphomutant abrogates interaction with Dab2 and fails to inhibit Wnt-induced TOP/FOPFlash transactivation ( Figure 4B and Figure  S6 ). In addition, while we do not perform a detailed analysis of the phosphotyrosine binding domain (PTB) of Dab2 binding to this S1579 site, there is indeed precedent for PTB domains binding to non-phosphotyrosine residues. This is reviewed in an article by B. Margolis entitled "The PTB domain: The name doesn't say it all" (Margolis, B. Trends Endocrinol Metab 10 (7), [262] [263] [264] [265] [266] [267] 1999) . There are numerous examples demonstrating, that despite its name, the PTB domain is involved in both phosphotyrosine-dependent and -independent interactions. In fact the PTB domain of Numb, another endocytic adaptor, interacts with its partner Nak through a CK2 consensus GFSNMSFEDFP (Dho et al., J. Biol. Chem. 273, 1998; Chien et al., Mol. Cell. Biol.18, 1998) . Despite this evidence, we do not dismiss the possible sequential phosphorylation of LRP6 as the referee suggests. We have also removed any explicit reference to docking sites in the Discussion.
2. liked to see whether the S1579A mutant LRP6 fails to partition with the clathrin fractions in Wnt-induced F9-Dab2 cells. This would strengthen the authors' contention that Dab2 controls the clathrin versus caveolin sorting of LRP6. We performed the experiment requested by the referee and demonstrate in Figure S9 that in the presence of Dab2 in F9-Dab2 cells, Wnt3A induces the S1579A phosphomutant to partition with caveolin & not with clathrin.
3. Is there a statement of which phospho-site on LRP6 is recognized by the anti-p-LRP6 antibody used in Fig. 2C ? As this antibody apparently only detects the LRP6 that associates with the caveolin fraction, the reader would have to divine that this refers to a phospho-site other than S1579. there is no description of what apigenin is or is expected to do within the cell. Why is this included in Fig. 3E (new Figure 4E) ? What is the reader supposed to derive from this observation?
We apologize for this omission and have corrected this to reflect that the antibody detects the phosphorylated S1490 site of LRP6. We have also indicated that apigenin is a selective CK2 inhibitor. Fig. 1 -the reader is left to wonder whether nystatin vs. MDC treatment would alter the biotin protection shown in 1F. Why was this not included?
4.
We have included new data demonstrating the effects of nystatin and MDC on LRP6 endocytosis as analyzed by biotin labeling as suggested by the referee. The new data is included in Figure S2 . Fig. 2C , the LRP6 distribution does not correlate tightly with the caveolin-enriched fractions.
5.
The authors need to comment on why this is the case. Our data show that caveolin distributes in fraction 3-5 and that LRP6 distributes between 3-6. This suggest that while all the LRP6 is not distributing with caveolin and that this is not a 1:1 correlation it does nevertheless show fairly strong co-distribution. In addition, upon Wnt stimulation it is clear that LRP6 and phospho-LRP6 shift toward the caveolin fractions and there is a better correlation between the distribution patterns of the two compared to in the absence of Wnt3A stimulation.
6. On pg. 8, the authors claim that they mutagenized "all possible phosphorylation sites" -does this refer only to S/T phosphorylation? or do they know that none of the Tyr's in this region are phosphorylated?
We have performed a more comprehensive analysis as suggested by the referee, mutating all of the possible phosphorylation sites within the ΔNG region, and found that only the S1579A mutant abolishes LRP6/Dab2 interactions (see Figure 4D and Figure S6A ). In addition, we also performed a TOP/FOPFlash luciferase activity assay in F9-Dab2 cells with the various phosphomutant LRP6 ΔNG constructs. The results presented in Figure S6B demonstrate that Dab2 attenuates all the phosphomutant LRP6 constructs in their ability to transactivate the promoter, except for the S1579A mutant. This indicates that the S1579A phosphomutant can still transactivate the TOP/FOPFlash promoter due to its inability to bind to and be inhibited by Dab2.
7. In Fig. 3G (new Figure 4G) , the authors need to comment on the multiple bands revealed in the anti-Dab2 blot. Is the fastest-migrating band a background band or is it an isoform that is resistant to the siDab2 treatment?
As the referee suggests, the fastest migrating band is a background band & we have delineated this fact in the figure. 8, in Fig. 5D (new Figure 6D) , the labels are not aligned properly.
We corrected this as the referee suggested. Fig. 7C (new Figure 8C) , the schematic diagram does not indicate GSK being sequestered along with Axin in the caveolin pathway, yet this seems to demonstrated in Fig. 2D .
9, in
We have amended the model to reflect this.
2nd Editorial Decision 08 March 2012
Thank you for the submission of your revised manuscript to The EMBO Journal. It has been sent to three of the original reviewers, who now consider that their concerns have been properly addressed and your manuscript is almost ready for publication.
Following referee #4's suggestion, I would like to ask you to carefully edit your manuscript to avoid typos and misinterpretations, although a complete re-writing of the paper will not be necessary. I have also noticed that the micrographs in your figures lack size bars, and these should be added for clarity.
As a novel initiative in The EMBO Journal, we now encourage the publication of source data, particularly for electrophoretic gels and blots, with the aim of making primary data more accessible and transparent to the reader. Although optional at the moment, would you be willing to provide a PDF file per figure that contains the original, uncropped and unprocessed scans of all or key gels used in the figures? The PDF files should be labeled with the appropriate figure/panel number, and should have molecular weight markers; further annotation could be useful but is not essential. The files will be published online with the article as supplementary "Source Data" files. If you have any questions regarding this initiative do not hesitate to contact me.
